| Tremelimumab studied in …STUDIED_INderived194 of 194show fewer |
|---|
| → studied in | NCT04988945Phase 2 · active not recruiting TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma · 194 trials list this drug (68 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07391670Phase 1 · recruiting A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab · 194 trials list this drug (68 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06109272Phase 2/Phase 3 · active not recruiting A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) · 194 trials list this drug (68 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03158064Phase 2 · active not recruiting Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors · 194 trials list this drug (68 active) | — | — | Germ Cell Tumor,Germinomatous Germ Cell Tumor,Dysgerminoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03847649Phase 2 · recruiting A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies · 194 trials list this drug (68 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02812420early Phase 1 · active not recruiting Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery · 194 trials list this drug (68 active) | — | — | Invasive Bladder Micropapillary Urothelial Carcinoma,Malignant Ureter Neoplasm,Malignant Urethral Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05883644Phase 3 · active not recruiting Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC) · 194 trials list this drug (68 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04817826Phase 2 · active not recruiting TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC. · 194 trials list this drug (68 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02962063Phase 1/Phase 2 · active not recruiting Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer · 194 trials list this drug (68 active) | — | — | Esophageal Adenocarcinoma,Gastroesophageal Junction Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03606967Phase 2 · recruiting Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer · 194 trials list this drug (68 active) | — | — | Invasive Breast Carcinoma,Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03937830Phase 2 · active not recruiting Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma · 194 trials list this drug (68 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04005690early Phase 1 · recruiting Targeted Pathway Inhibition in Patients With Pancreatic Cancer · 194 trials list this drug (68 active) | — | — | Malignant Pancreatic Neoplasm,Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06921785Phase 3 · recruiting Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma · 194 trials list this drug (68 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06855225Phase 2 · not yet recruiting A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma · 194 trials list this drug (68 active) | — | — | Liver Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03057106Phase 2 · active not recruiting Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC · 194 trials list this drug (68 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04034927Phase 2 · active not recruiting Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer · 194 trials list this drug (68 active) | — | — | Fallopian Tube Endometrioid Tumor,Primary Peritoneal Carcinoma,Fallopian Tube Endometrioid Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03682068Phase 3 · active not recruiting Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer · 194 trials list this drug (68 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03965468Phase 2 · active not recruiting Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC · 194 trials list this drug (68 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07166406Phase 3 · recruiting Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial · 194 trials list this drug (68 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03283605Phase 1/Phase 2 · completed Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas · 194 trials list this drug (68 active) | — | — | Squamous Cell Carcinoma,Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05701488Phase 1 · active not recruiting SIRT With Tremelimumab and Durvalumab for Resectable HCC · 194 trials list this drug (68 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02453282Phase 3 · active not recruiting Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) · 194 trials list this drug (68 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02519348Phase 2 · active not recruiting A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma · 194 trials list this drug (68 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03026062Phase 2 · completed Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer · 194 trials list this drug (68 active) | — | — | Primary Peritoneal Carcinoma,Ovarian Carcinoma,Platinum-Resistant Primary Peritoneal Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02888743Phase 2 · active not recruiting Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer · 194 trials list this drug (68 active) | — | — | Colorectal Neoplasm,Lung Non-Small Cell Carcinoma,Colorectal Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03581487Phase 1/Phase 2 · completed Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer · 194 trials list this drug (68 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06710223Phase 1 · active not recruiting Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab · 194 trials list this drug (68 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01843374Phase 2 · active not recruiting Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma · 194 trials list this drug (68 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03298451Phase 3 · active not recruiting Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma · 194 trials list this drug (68 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04395079Phase 2 · active not recruiting Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies · 194 trials list this drug (68 active) | — | — | Malignant Female Reproductive System Neoplasm,Platinum-Resistant Malignant Female Reproductive System Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03043872Phase 3 · active not recruiting Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN) · 194 trials list this drug (68 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03075527Phase 2 · terminated A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma · 194 trials list this drug (68 active) | — | — | Malignant Mesothelioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03317158Phase 1/Phase 2 · active not recruiting Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder · 194 trials list this drug (68 active) | — | — | Urothelial Carcinoma,Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02516241Phase 3 · active not recruiting Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer · 194 trials list this drug (68 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05301842Phase 3 · active not recruiting Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC · 194 trials list this drug (68 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06117891active not recruiting An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery · 194 trials list this drug (68 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06824363early Phase 1 · recruiting ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu · 194 trials list this drug (68 active) | — | — | Adult Solid Neoplasm,Malignant Solid Neoplasm,Esophageal Adenocarcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06008093Phase 2 · active not recruiting A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS · 194 trials list this drug (68 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05557838Phase 3 · active not recruiting Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC · 194 trials list this drug (68 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04522544Phase 2 · active not recruiting Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC · 194 trials list this drug (68 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04960709Phase 3 · active not recruiting Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin · 194 trials list this drug (68 active) | — | — | Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06680739Phase 2 · recruiting Single cEll pRofiling PErsistaNce To ImmuNothErapy · 194 trials list this drug (68 active) | — | — | Malignant Colorectal Neoplasm,Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03237377Phase 2 · terminated Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer · 194 trials list this drug (68 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06058663Phase 1 · recruiting Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma · 194 trials list this drug (68 active) | — | — | Intrahepatic Cholangiocarcinoma,Oligometastatic Intrahepatic Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07081633Phase 2 · active not recruiting Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma · 194 trials list this drug (68 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03601455Phase 2 · active not recruiting Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer · 194 trials list this drug (68 active) | — | — | Bladder Urothelial Carcinoma,Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06564623Phase 1 · recruiting Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC) · 194 trials list this drug (68 active) | — | — | Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05027425Phase 2 · terminated Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant · 194 trials list this drug (68 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07122089Phase 2 · recruiting Evaluation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Carcinoma With Portal Vein Thrombosis · 194 trials list this drug (68 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03482102Phase 2 · active not recruiting Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer · 194 trials list this drug (68 active) | — | — | Hepatocellular Carcinoma,Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04585490Phase 3 · recruiting Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC · 194 trials list this drug (68 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04605731Phase 1 · active not recruiting Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer · 194 trials list this drug (68 active) | — | — | Hepatocellular Carcinoma,BCLC Stage B Hepatocellular Carcinoma,BCLC Stage C Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07288034Phase 2 · recruiting Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial · 194 trials list this drug (68 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07511504Phase 2 · not yet recruiting Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma · 194 trials list this drug (68 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03923270Phase 1 · active not recruiting Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer · 194 trials list this drug (68 active) | — | — | Lung Neoplasm,Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02537418Phase 1 · active not recruiting Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens · 194 trials list this drug (68 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03410615Phase 2 · active not recruiting Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC · 194 trials list this drug (68 active) | — | — | Oropharyngeal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04499053Phase 2 · recruiting Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer · 194 trials list this drug (68 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03164616Phase 3 · active not recruiting Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). · 194 trials list this drug (68 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03753919Phase 2 · terminated Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial · 194 trials list this drug (68 active) | — | — | Thyroid Gland Follicular Carcinoma,Malignant Thyroid Gland Neoplasm,Thyroid Gland Papillary Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06608940Phase 1/Phase 2 · withdrawn BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma · 194 trials list this drug (68 active) | — | — | Liver Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02499328Phase 1/Phase 2 · completed Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck · 194 trials list this drug (68 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07174570Phase 2 · recruiting Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer · 194 trials list this drug (68 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03539822Phase 1/Phase 2 · recruiting Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies · 194 trials list this drug (68 active) | — | — | Malignant Gastric Neoplasm,Hepatocellular Carcinoma,Esophageal Adenocarcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06526104Phase 2 · recruiting Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis · 194 trials list this drug (68 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05380713Phase 2 · completed ......SMARTEST Trial...... · 194 trials list this drug (68 active) | — | — | Malignant Mesothelioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04430452Phase 2 · recruiting Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma · 194 trials list this drug (68 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04238637Phase 2 · active not recruiting Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC) · 194 trials list this drug (68 active) | — | — | Intrahepatic Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02639026Phase 1 · completed Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers · 194 trials list this drug (68 active) | — | — | Malignant Breast Neoplasm,Melanoma,Malignant Pancreatic Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03703297Phase 3 · active not recruiting Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy · 194 trials list this drug (68 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06994299Phase 2 · withdrawn A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular Carcinoma · 194 trials list this drug (68 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06698250Phase 2 · recruiting Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA) · 194 trials list this drug (68 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02938793Phase 2 · terminated Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors · 194 trials list this drug (68 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03019003Phase 1 · completed Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients · 194 trials list this drug (68 active) | — | — | Malignant Head and Neck Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06999694Phase 2 · recruiting Proton Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC · 194 trials list this drug (68 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03638141Phase 2 · completed CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab · 194 trials list this drug (68 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03704480Phase 2 · active not recruiting Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy. · 194 trials list this drug (68 active) | — | — | Biliary Tract Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05451043Phase 2 · recruiting Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED) · 194 trials list this drug (68 active) | — | — | Malignant Pancreatic Neoplasm,Hepatocellular Carcinoma,Malignant Biliary Tract Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02815995Phase 2 · completed Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes · 194 trials list this drug (68 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06999707Phase 2 · recruiting Photon Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC · 194 trials list this drug (68 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03277482Phase 1 · terminated Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer · 194 trials list this drug (68 active) | — | — | Malignant Ovarian Neoplasm,Ovarian Carcinoma,Cervical Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02571725Phase 1/Phase 2 · active not recruiting PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer · 194 trials list this drug (68 active) | — | — | Peritoneal Neoplasm,Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02788773Phase 2 · completed Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer · 194 trials list this drug (68 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03212469Phase 1/Phase 2 · completed A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer · 194 trials list this drug (68 active) | — | — | Malignant Lung Neoplasm,Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05239169Phase 2 · completed Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer · 194 trials list this drug (68 active) | — | — | Intrahepatic Cholangiocarcinoma,Malignant Biliary Tract Neoplasm,Distal Cholangiocarcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02879162Phase 2 · completed Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours · 194 trials list this drug (68 active) | — | — | Rare Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03871036Phase 1/Phase 2 · completed Improve Checkpoint-blockade Response in Advanced Urothelial Cancer · 194 trials list this drug (68 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03509012Phase 1 · completed Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors · 194 trials list this drug (68 active) | — | — | Carcinoma,Lung Non-Small Cell Carcinoma,Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03095274Phase 2 · completed Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin · 194 trials list this drug (68 active) | — | — | Lung Neuroendocrine Neoplasm,Neuroendocrine Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03702179Phase 2 · completed Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach · 194 trials list this drug (68 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05000710Phase 2 · active not recruiting Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy · 194 trials list this drug (68 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02953457Phase 2 · completed Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation · 194 trials list this drug (68 active) | — | — | Primary Peritoneal Carcinoma,Ovarian Carcinoma,Fallopian Tube Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06017297Phase 2 · withdrawn Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma · 194 trials list this drug (68 active) | — | — | Carcinoma,Malignant Biliary Tract Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04287894Phase 1 · terminated Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment · 194 trials list this drug (68 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02819596Phase 2 · completed MEDI4736 Combinations in Metastatic Renal Cell Carcinoma · 194 trials list this drug (68 active) | — | — | Clear Cell Renal Cell Carcinoma,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03204812Phase 2 · completed Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer · 194 trials list this drug (68 active) | — | — | Prostate Adenocarcinoma,Malignant Prostate Neoplasm,Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05440864Phase 2 · recruiting Durvalumab and Tremelimumab in Resectable HCC · 194 trials list this drug (68 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02754856Phase 1 · completed Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery · 194 trials list this drug (68 active) | — | — | Colorectal Neoplasm,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04156087Phase 2 · completed Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer · 194 trials list this drug (68 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03693612Phase 1/Phase 2 · completed GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors · 194 trials list this drug (68 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02352948Phase 3 · completed A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer · 194 trials list this drug (68 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03959293Phase 2 · unknown Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma · 194 trials list this drug (68 active) | — | — | Malignant Gastric Neoplasm,Gastric Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03557918Phase 2 · completed Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer · 194 trials list this drug (68 active) | — | — | Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03132467early Phase 1 · completed Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer · 194 trials list this drug (68 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04159974Phase 2 · unknown RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus · 194 trials list this drug (68 active) | — | — | Esophageal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02301130Phase 1 · completed Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors · 194 trials list this drug (68 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03046862Phase 2 · unknown Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer · 194 trials list this drug (68 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02735239Phase 1/Phase 2 · completed Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer · 194 trials list this drug (68 active) | — | — | Malignant Esophageal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02762006Phase 1 · completed Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma · 194 trials list this drug (68 active) | — | — | Malignant Kidney Neoplasm,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03549715Phase 1/Phase 2 · unknown NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma · 194 trials list this drug (68 active) | — | — | Invasive Bladder Urothelial Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03015129Phase 2 · completed A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer · 194 trials list this drug (68 active) | — | — | Uterine Corpus Carcinosarcoma,Endometrial Carcinoma,Endometrial Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02870920Phase 2 · completed Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care in Patients With Advanced Colorectal Cancer · 194 trials list this drug (68 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03618134Phase 1/Phase 2 · terminated Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner · 194 trials list this drug (68 active) | — | — | Oropharyngeal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02616185Phase 1 · terminated A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR) · 194 trials list this drug (68 active) | — | — | Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05120622Phase 1/Phase 2 · withdrawn Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer · 194 trials list this drug (68 active) | — | — | Bladder Neoplasm,Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03206073Phase 1/Phase 2 · completed A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination With Immune Checkpoint Inhibition in Refractory Colorectal Cancer · 194 trials list this drug (68 active) | — | — | Malignant Neoplasm,Colorectal Neoplasm,Colorectal Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02718911Phase 1 · completed A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors · 194 trials list this drug (68 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03452332Phase 1 · completed Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers · 194 trials list this drug (68 active) | — | — | Cervical Adenocarcinoma,Cervical Squamous Cell Carcinoma,Vaginal Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03624231Phase 2 · completed Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC · 194 trials list this drug (68 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03473574Phase 2 · completed Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients · 194 trials list this drug (68 active) | — | — | Cholangiocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03522584Phase 1/Phase 2 · terminated Durvalumab, Tremelimumab and Hypofractionated Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma · 194 trials list this drug (68 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03373760Phase 2 · completed Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer · 194 trials list this drug (68 active) | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04625699Phase 2 · withdrawn Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment · 194 trials list this drug (68 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02154490completed Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer · 194 trials list this drug (68 active) | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03275597Phase 1 · terminated Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition · 194 trials list this drug (68 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02141542Phase 1 · completed Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma · 194 trials list this drug (68 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03994393Phase 2 · unknown Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease. · 194 trials list this drug (68 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03472274Phase 2 · completed Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO) · 194 trials list this drug (68 active) | — | — | Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05809869Phase 2 · unknown Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma · 194 trials list this drug (68 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02821754Phase 2 · completed A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) · 194 trials list this drug (68 active) | — | — | Hepatocellular Carcinoma,Malignant Bile Duct Neoplasm,Malignant Liver Neoplasm+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03975114Phase 2 · unknown A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5) · 194 trials list this drug (68 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04107168unknown Microbiome Immunotherapy Toxicity and Response Evaluation · 194 trials list this drug (68 active) | — | — | Melanoma,Malignant Lung Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03982173Phase 2 · withdrawn Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors · 194 trials list this drug (68 active) | — | — | Prostate Adenocarcinoma,Esophageal Adenocarcinoma,Gastric Adenocarcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05345678approved for marketing Himalaya Early Access Program · 194 trials list this drug (68 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03007407Phase 2 · completed Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy · 194 trials list this drug (68 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02643303Phase 1/Phase 2 · completed A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers · 194 trials list this drug (68 active) | — | — | Solid Neoplasm,Malignant Breast Neoplasm,Melanoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01975831Phase 1 · completed A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab · 194 trials list this drug (68 active) | — | — | Malignant Breast Neoplasm,Malignant Ovarian Neoplasm,Malignant Colorectal Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02716805Phase 1 · terminated Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant · 194 trials list this drug (68 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03164772Phase 1/Phase 2 · completed Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC · 194 trials list this drug (68 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02592551Phase 2 · completed MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma · 194 trials list this drug (68 active) | — | — | Malignant Mesothelioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02563925NA · completed Brain Irradiation and Tremelimumab in Metastatic Breast Cancer · 194 trials list this drug (68 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02626130early Phase 1 · completed Tremelimumab With or Without Cryoablation in Treating Patients With Metastatic Kidney Cancer · 194 trials list this drug (68 active) | — | — | Clear Cell Renal Cell Carcinoma,Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03122509Phase 2 · completed A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal Cancer · 194 trials list this drug (68 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03122496Phase 1 · completed Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer · 194 trials list this drug (68 active) | — | — | Thyroid Gland Anaplastic Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03101475Phase 2 · completed Synergism of Immunomodulation and Tumor Ablation · 194 trials list this drug (68 active) | — | — | Colorectal Neoplasm,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02536794Phase 2 · completed MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer · 194 trials list this drug (68 active) | — | — | Malignant Breast Neoplasm,Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02794883Phase 2 · completed Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma · 194 trials list this drug (68 active) | — | — | Glioblastoma,Malignant Glioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03319316Phase 2 · withdrawn Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC) · 194 trials list this drug (68 active) | — | — | Lung Non-Squamous Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02551159Phase 3 · completed Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer · 194 trials list this drug (68 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02701400Phase 2 · completed Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer · 194 trials list this drug (68 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03081923Phase 2 · terminated Durvalumab Alone or With Tremelimumab in Refractory Germ Cell Tumors · 194 trials list this drug (68 active) | — | — | Germ Cell Tumor | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02311361Phase 1/Phase 2 · completed Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer · 194 trials list this drug (68 active) | — | — | Malignant Pancreatic Neoplasm,Pancreatic Neoplasm,Pancreatic Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02485990Phase 1 · terminated Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma) · 194 trials list this drug (68 active) | — | — | Primary Peritoneal Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03144778Phase 1 · completed Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer · 194 trials list this drug (68 active) | — | — | Head and Neck Squamous Cell Carcinoma,Oropharyngeal Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01938612Phase 1 · completed A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours · 194 trials list this drug (68 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00471887Phase 2 · completed Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma · 194 trials list this drug (68 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02319044Phase 2 · completed Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck · 194 trials list this drug (68 active) | — | — | Head and Neck Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03288532Phase 3 · recruiting Renal Adjuvant MultiPle Arm Randomised Trial · 194 trials list this drug (68 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02658214Phase 1 · completed Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors · 194 trials list this drug (68 active) | — | — | Carcinoma,Gastric Neoplasm,Peritoneal Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03598816Phase 2 · withdrawn PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma · 194 trials list this drug (68 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04073160Phase 1 · withdrawn TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer · 194 trials list this drug (68 active) | — | — | Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03234153Phase 2 · terminated Neoadjuvant Immunotherapy With Durvalumab and Tremelimumab for Bladder Cancer Patients Ineligible for Cisplatin · 194 trials list this drug (68 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01103635Phase 1 · completed Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma · 194 trials list this drug (68 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02261220Phase 1 · completed A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors · 194 trials list this drug (68 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04274816Phase 1 · completed Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma · 194 trials list this drug (68 active) | — | — | Cutaneous Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03005002Phase 1 · completed Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver · 194 trials list this drug (68 active) | — | — | Colorectal Neoplasm,Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01853618Phase 1/Phase 2 · completed Tremelimumab With Chemoembolization or Ablation for Liver Cancer · 194 trials list this drug (68 active) | — | — | Hepatocellular Carcinoma,Malignant Liver Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02586987Phase 1 · completed A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours · 194 trials list this drug (68 active) | — | — | Malignant Breast Neoplasm,Melanoma,Head and Neck Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02000947Phase 1 · completed A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer · 194 trials list this drug (68 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02705482Phase 1 · completed A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors · 194 trials list this drug (68 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02179671Phase 2 · completed Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer · 194 trials list this drug (68 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02868632Phase 1 · withdrawn Study of Immune Checkpoint Inhibition With Radiation Therapy in Unresectable, Non-metastatic Pancreatic Cancer · 194 trials list this drug (68 active) | — | — | Malignant Pancreatic Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02549651Phase 1 · completed MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023) · 194 trials list this drug (68 active) | — | — | Diffuse Large B-Cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02141347Phase 1 · completed Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma · 194 trials list this drug (68 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03085849Phase 1 · completed SGI-110 Plus Durvalumab/Tremelimumab in SCLC · 194 trials list this drug (68 active) | — | — | Lung Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03130764Phase 2 · withdrawn Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC · 194 trials list this drug (68 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01034787Phase 2 · completed Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma · 194 trials list this drug (68 active) | — | — | Uveal Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02262741Phase 1 · completed A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer · 194 trials list this drug (68 active) | — | — | Head and Neck Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03150836Phase 2 · withdrawn Radiation Therapy and Durvalumab, With or Without Tremelimumab, in Patients With Bladder Cancer · 194 trials list this drug (68 active) | — | — | Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02040064Phase 1 · completed Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients · 194 trials list this drug (68 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00897312terminated Effect of Biological Therapy on Biomarkers in Patients With Untreated Hepatitis C, Metastatic Melanoma, or Crohn Disease · 194 trials list this drug (68 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01334099Phase 1 · terminated Safety Study of Radiation and CP-675,206 Infusion for Breast Cancer Patients · 194 trials list this drug (68 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01655888Phase 2 · unknown The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma · 194 trials list this drug (68 active) | — | — | Malignant Mesothelioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01649024Phase 2 · unknown A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma · 194 trials list this drug (68 active) | — | — | Malignant Mesothelioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00257205Phase 3 · completed CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy · 194 trials list this drug (68 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01008358Phase 2 · completed Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients With Advanced Hepatocellular Carcinoma · 194 trials list this drug (68 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00254579Phase 2 · completed Study of CP-675,206 in Refractory Melanoma · 194 trials list this drug (68 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00312975Phase 2 · completed Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC) · 194 trials list this drug (68 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00313794Phase 2 · completed Study of Ticilimumab in Patients With Metastatic Colorectal Cancer Whose Disease Had Progressed After Treatment · 194 trials list this drug (68 active) | — | — | Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00086489Phase 2 · completed CP-675,206 In Patients With Advanced Melanoma · 194 trials list this drug (68 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00372853Phase 1 · completed Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma · 194 trials list this drug (68 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00431275Phase 1 · completed Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody · 194 trials list this drug (68 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00585000Phase 1 · terminated A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma · 194 trials list this drug (68 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00584493no longer available Treatment Use Study for Advanced Melanoma. · 194 trials list this drug (68 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |